Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia-Review and Expert Opinion.

Anamorelin was associated with a numerically lower reduction in the co-primary endpoint of handgrip strength, when compared with placebo, although the results did not reach statistical significance (−1.10 kg [95% CI: −1.69, −0.40] vs. −1.58 kg [95% CI: −2.99, −1.14]; p = 0.15).

also in 111,027 other papers

In summary, the ROMANA trials have provided valuable knowledge, thus highlighting the therapeutic effects of anamorelin as an initial, but highly significant, step [ 96 ] toward achieving overall management of cancer cachexia through future multimodal treatment.

also in 132,142 other papers